Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest update is out from Mayne Pharma Group ( (AU:MYX) ).
UBS Group AG and its related entities have increased their voting power in Mayne Pharma Group Limited from 6.38% to 7.40%, as of April 14, 2025. This change in substantial holding indicates a growing interest and investment in the company, potentially impacting its market positioning and signaling confidence in its future prospects.
More about Mayne Pharma Group
Mayne Pharma Group Limited operates in the pharmaceutical industry, focusing on the development and manufacturing of branded and generic pharmaceutical products. The company is known for its commitment to providing high-quality medications and has a significant presence in the global pharmaceutical market.
YTD Price Performance: 47.57%
Average Trading Volume: 2,022
Technical Sentiment Signal: Sell
Current Market Cap: $360M
For detailed information about MYX stock, go to TipRanks’ Stock Analysis page.